Most cited papers from Ruhrlandklinik

Ruhrlandklinik

What are the most cited papers from Ruhrlandklinik?

The most cited paper from Ruhrlandklinik is "Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer" (Julie Renee Brahmer et al., 2015), with 8,632 citations. Next come "The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer" (4,749) and "Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis" (4,731).

Published TypeFieldAccessAuthorsCitations

Showing 50 of 61 papers. Every paper with more than 245 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer Julie Renee Brahmer et al. · New England Journal of Medicine Open access	31 May 2015	8,632
2	The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer Peter Goldstraw et al. · Journal of Thoracic Oncology Open access152 authors	2016	4,749
3	Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis Luca Richeldi et al. · New England Journal of Medicine Open access	18 May 2014	4,731
4	Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials Paul W. Noble, Carlo Albera, Williamson Z. Bradford et al. · The Lancet	May 2011	2,182
5	Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis Luca Richeldi, Ulrich Costabel, Moisés Selman et al. · New England Journal of Medicine Open access	21 Sep 2011	1,178
6	Adaptive Servo-Ventilation for Central Sleep Apnea in Systolic Heart Failure Martín Cowie, Holger Woehrle, Karl Wegscheider et al. · New England Journal of Medicine Open access	Sep 2015	1,109
7	High-Dose Acetylcysteine in Idiopathic Pulmonary Fibrosis Maurits Demedts et al. · New England Journal of Medicine Open access	23 Nov 2005	986
8	Sleep-Disordered Breathing in Patients with Symptomatic Heart Failure A Contemporary Study of Prevalence in and Characteristics of 700 Patients Olaf Oldenburg, Barbara Lamp, Lothar Faber et al. · European Journal of Heart Failure	6 Oct 2006	760
9	Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer Hossein Borghaei et al. · Journal of Clinical Oncology Open access	15 Jan 2021	683
10	ERS clinical practice guidelines on treatment of sarcoidosis Robert Phillip Baughman et al. · European Respiratory Journal Open access	17 Jun 2021	628
11	Adaptive Pressure Support Servo-Ventilation Helmut Teschler, JENS DÖHRING, Youming Wang et al. · American Journal of Respiratory and Critical Care Medicine	Aug 2001	608
12	Mutations in DNAH5 cause primary ciliary dyskinesia and randomization of left–right asymmetry Heike Olbrich, Karsten Häffner, Andreas Kispert et al. · Nature Genetics	14 Jan 2002	560
13	Effect of interferon gamma-1b on survival in patients with idiopathic pulmonary fibrosis (INSPIRE): a multicentre, randomised, placebo-controlled trial Talmadge E. King, Carlo Albera, Williamson Z. Bradford et al. · The Lancet Open access	30 Jun 2009	537
14	Forced Vital Capacity in Patients with Idiopathic Pulmonary Fibrosis: Test Properties and Minimal Clinically Important Difference Roland M. du Bois, Derek A. Weycker, Carlo Albera et al. · American Journal of Respiratory and Critical Care Medicine Open access	22 Sep 2011	535
15	Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial Jürgen Behr et al. · The Lancet Respiratory Medicine Open access107 authors	30 Mar 2021	528
16	Ultrasound guidance versus anatomical landmarks for internal jugular vein catheterization Patrick Braß, Martin Hellmich, Laurentius Kolodziej et al. · Cochrane Database of Systematic Reviews Open access	9 Jan 2015	473
17	Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials Paul W. Noble, Carlo Albera, Williamson Z. Bradford et al. · European Respiratory Journal Open access	2 Dec 2015	472
18	Six-Minute-Walk Test in Idiopathic Pulmonary Fibrosis: Test Validation and Minimal Clinically Important Difference Roland M. du Bois, Derek A. Weycker, Carlo Albera et al. · American Journal of Respiratory and Critical Care Medicine Open access	4 Dec 2010	467
19	ATS/ERS international multidisciplinary consensus classification of the idiopathic interstitial pneumonias: Table 1— Maurits Demedts, Ulrich Costabel · European Respiratory Journal Open access	May 2002	463
20	Quantitative Analysis of Mycobacterial and Propionibacterial DNA in Lymph Nodes of Japanese and European Patients with Sarcoidosis Yoshinobu Eishi, Moritaka Suga, Ikuo Ishige et al. · Journal of Clinical Microbiology Open access	2002	445
21	Ascertainment of Individual Risk of Mortality for Patients with Idiopathic Pulmonary Fibrosis Roland M. du Bois, Derek A. Weycker, Carlo Albera et al. · American Journal of Respiratory and Critical Care Medicine Open access	26 May 2011	432
22	The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the Clinical and Pathologic Staging of Small Cell Lung Cancer in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer Andrew Gordon Nicholson et al. · Journal of Thoracic Oncology Open access152 authors	24 Dec 2015	429
23	Sarcoidosis in America. Analysis Based on Health Care Use Robert P. Baughman, S Field, Ulrich Costabel et al. · Annals of the American Thoracic Society	Aug 2016	428
24	The IASLC Lung Cancer Staging Project Wilfried Eberhardt, Alan Mitchell, John Crowley et al. · Journal of Thoracic Oncology Open access	4 Sep 2015	419
25	Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study for the ERIVANCE BCC Investigators, Aleksandar Sekulić, Michael Robert Migden et al. · BMC Cancer Open access	16 May 2017	416
26	2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer Wilfried Eberhardt et al. · Annals of Oncology Open access	21 Apr 2015	405
27	A Multicenter Randomized Controlled Trial of Zephyr Endobronchial Valve Treatment in Heterogeneous Emphysema (TRANSFORM) Samuel V. Kemp et al. · American Journal of Respiratory and Critical Care Medicine Open access	8 Sep 2017	398
28	Pulmonary alveolar proteinosis Bruce C. Trapnell, Koh Nakata, Francesco Bonella et al. · Nature Reviews Disease Primers Review	7 Mar 2019	397
29	Clinical features and virological analysis of a case of Middle East respiratory syndrome coronavirus infection Christian Drosten et al. · The Lancet Infectious Diseases Open access	16 Jun 2013	391
30	Treatment of Idiopathic Pulmonary Fibrosis with Etanercept: An Exploratory, Placebo-controlled Trial Ganesh Raghu, Kevin M. Brown, Ulrich Costabel et al. · American Journal of Respiratory and Critical Care Medicine	31 Jul 2008	380
31	Assays for laboratory confirmation of novel human coronavirus (hCoV-EMC) infections Victor M. Corman, Marcel A. Müller, Ulrich Costabel et al. · Eurosurveillance Open access	6 Dec 2012	380
32	Endobronchial Valve Therapy in Patients with Homogeneous Emphysema: Results from the IMPACT Study Arschang Valipour, Dirk‐Jan Slebos, Felix J.F. Herth et al. · American Journal of Respiratory and Critical Care Medicine	31 Aug 2016	375
33	Brain Representation of Active and Passive Movements Cornelius Weiller, Markus Jüptner, Stuart J. Fellows et al. · NeuroImage	Oct 1996	373
34	Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non–Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE) Wilfried Eberhardt et al. · Journal of Clinical Oncology	2 Nov 2015	367
35	Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities Peter Myles George, Paolo Spagnolo, Michael Kreuter et al. · The Lancet Respiratory Medicine Open access	Sep 2020	356
36	Transbronchial Cryobiopsies for the Diagnosis of Diffuse Parenchymal Lung Diseases: Expert Statement from the Cryobiopsy Working Group on Safety and Utility and a Call for Standardization of the Procedure Jürgen Hetzel et al. · Respiration Open access	2018	354
37	Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis Steven D. Nathan, Carlo Albera, Williamson Z. Bradford et al. · The Lancet Respiratory Medicine	18 Nov 2016	341
38	Bronchoscopic Lung Cryobiopsy Increases Diagnostic Confidence in the Multidisciplinary Diagnosis of Idiopathic Pulmonary Fibrosis Sara Tomassetti, Athol Umfrey Wells, Ulrich Costabel et al. · American Journal of Respiratory and Critical Care Medicine	12 Nov 2015	340
39	Efficacy of infliximab in extrapulmonary sarcoidosis: results from a randomised trial Marc A. Judson, Robert P. Baughman, Ulrich Costabel et al. · European Respiratory Journal Open access	6 Feb 2008	324
40	Ultrasound guidance versus anatomical landmarks for subclavian or femoral vein catheterization Patrick Braß, Martin Hellmich, Laurentius Kolodziej et al. · Cochrane Database of Systematic Reviews Open access	9 Jan 2015	321
41	Does alpha1-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary alpha1-antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) alpha1-AT study group Niels Jørgen Seersholm, Marion Wencker, Norbert Banik et al. · European Respiratory Journal Open access	Oct 1997	309
42	Alpha sympathomimetic inhibition of adrenergic and cholinergic transmission in the rabbit heart Klaus Starke · Naunyn-Schmiedeberg s Archives of Pharmacology	1972	302
43	Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis LISA H. LANCASTER, João A. de Andrade, Joseph D. Zibrak et al. · European Respiratory Review Open access	6 Dec 2017	298
44	A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Compare the Efficacy and Safety of Three Doses of Botulinum Toxin Type A (Dysport) With Placebo in Upper Limb Spasticity After Stroke A. M. O. Bakheit, Alfred F. Thilmann, Anthony B. Ward et al. · Stroke Open access	Oct 2000	298
45	Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial Luca Richeldi, Evans R. Fernández Pérez, Ulrich Costabel et al. · The Lancet Respiratory Medicine	28 Sep 2019	294
46	Determination of carbonyl groups in oxidatively modified proteins by reduction with tritiated sodium borohydride Anke-G. Lenz, Ulrich Costabel, Shmuel Shaltiel et al. · Analytical Biochemistry	Mar 1989	287
47	Efficacy of Nintedanib in Idiopathic Pulmonary Fibrosis across Prespecified Subgroups in INPULSIS Ulrich Costabel, Yoshikazu Inoue, Luca Richeldi et al. · American Journal of Respiratory and Critical Care Medicine	22 Sep 2015	283
48	Triple Therapy for Cystic Fibrosis Phe508del –Gating and –Residual Function Genotypes Peter J. Barry et al. · New England Journal of Medicine Open access	25 Aug 2021	282
49	Eosinophilic and Noneosinophilic Asthma Liam Gabriel Heaney et al. · CHEST Journal Open access	19 Apr 2021	282
50	Interstitial lung disease Katerina M. Antoniou, George A. Margaritopoulos, Sara Tomassetti et al. · European Respiratory Review Open access	28 Feb 2014	279

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.